Too many treatments for Parkinson's disease: How should they be used?

Wisconsin Medical Journal

Volumn 99, Issue 3, 2000, Pages

  Reynolds Jr , Norman C ^a,b   Terry, L Cass ^a,b   Mark, Leighton P ^a,b   Prieto, Thomas E ^a,b   Mueller, Wade R ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Department of Neurology ^*

Author keywords

[No Author keywords available]

Indexed keywords

DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; HUMAN; PARKINSON DISEASE; TREATMENT INDICATION;

ANTIPARKINSON AGENTS; CARBIDOPA; DECISION MAKING; DRUG COMBINATIONS; HUMANS; LEVODOPA; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE; STEREOTAXIC TECHNIQUES;

EID: 6744242023     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jankovic J, McDermott N, Carter J, et al. Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. Neurology 1990;40:1529-1534.
2. Huber S, Paulson G, Shuttleworth E. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease. J Neurol, Neurosurg, Psychiatry 1988;51:855-858.
3. Parkinson J. An essay on the Shaking Palsy. London: Sherood, Neely and Jones, 1817.
4. Hoehn, MM, Yahr MD. Parkinsonism: Onset, progression, mortality. Neurology. 1967;17:427-442.
5. Charot, C-M. Lecons sur les maladies du systeme nerveus. A Delahaye, Paris, 1867:1872-1873.
6. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912;34:295-489.
7. Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotaxic apparatus for operations on the human brain. Science 1946;106:349-350.
8. Hassler R, Mundinger F, Riechert T. Stereotaxis in Parkinsonian Syndromes, Berlin: Springer-Verlag, 1979.
9. Meyers R. Surgical interruption of the pallidofugal fibers: its effect on the syndrome paralysis agitans and technical considerations in its application. NY State J Med 1942;42:317-325.
10. Carlsson A, Lindquist M, Magnusson T. 3,4-dihydroxyphenylalanine and 5-hydroxytrytophan as reserpine antagonists. Nature 1957;180:1200-1201.
11. Ehnnger H, Homykiewitz O. Verteilung von Noradrenalin and dopamin (3-hydroxytyramin) im Gehim des Menschen and ihr Verhalten bei Erkrangungendes extrapyramidalen systems. Klin Wochenschr 1960;38:1236-1239.
12. Cotzias GC, Van Woert MH, Schiffer L. Aromatic amino acids and modification of parkinsonism. New Engl J Med 1967;276:374-379.
13. Papavasiliou PS, Cotzias GC, Duby S, et al. Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N Eng J Med 1972;285:814.
14. Kondo T, Ito T, Sugita Y. Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum. Ann NY Acad Sci 1994;738:222-229.
15. Graham DG, Tiffany SM, Bell WR, Gutknecht WE Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6 hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-653.
16. Davis GC, Williams AC, Markey SP, et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1979;1:249-254.
17. Birkmayer W, Riederer P, Youdim MBH, Linauer W. The potentiation of the anti-akinetic effect after levodopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm 1975;36:303-326.
18. Kaakkola S, Wurtman RJ. Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. Brain Res 1992;587:241-249.
19. Olanow CW, Freeman TB, Kordower JH. Transplantation strategies for Parkinson's disease. In Watts RL, Koller WC (eds): Movement Disorders, Neurologic Principles and Practice. New York: McGraw-Hill 1997, pp. 222-236.
20. DeLong MR, Crutcher MD, Georgopoulos AP. Primate globus pallidus and subthalamic nucleus functional organization. J Neurophysiol 1985;53:530-534.